July 3, 2018 08:09 AM EDT
Bioregnum
Opinion

Re­gen­eron, Sanofi show re­straint on Dupix­ent price hike, but Pfiz­er’s hard charge con­tin­ues to spur calls for a rad­i­cal change-up

BIOREG­NUM — the view from John Car­roll

With the price of drugs front and cen­ter in Wash­ing­ton DC these days, Re­gen­eron and Sanofi are at­tract­ing …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

No­vo Nordisk is feel­ing the com­pe­ti­tion from com­pound­ed GLP-1s, ex­ec says

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

Ku­ra's AML drug pass­es key study in ad­vanced pa­tients, plans next steps with FDA and new­ly di­ag­nosed stud­ies

Small per­son­al­ized vac­cine tri­al sees progress in late-stage kid­ney can­cer

Eye­Point shares more mid-stage da­ta for ther­a­py try­ing to com­pete with Re­gen­eron's Eylea

Bris­tol My­ers, Ky­owa Kirin dis­close lay­offs

A service from the Financial Times